BlaidsX Neuro vs Resound Vivia 9 60S microRIE

The BlaidsX Neuro is a mid-priced behind-the-ear OTC hearing aid priced at $799, earning a B grade with a SoundScore of 3.4/5 in our lab testing. This places it in the top 68% of OTC hearing aids tested, though it falls below the category average of 3.71. In our testing, the BlaidsX Neuro showed notable strengths in speech clarity for quiet environments, scoring 0.54 points above the category average. Feedback handling was excellent at 5.0/5, ranking among the best we've measured and 0.46 points above average. These results suggest the device may work well for conversations in calm settings where background noise isn't a factor. However, the device showed significant limitations in other areas. Speech in noise performance scored low at 1.0/5, falling 0.48 points below the category average—a concern for users who need help in challenging listening environments. Own-voice comfort also scored below average at 1.7/5, and music streaming scored 0.0/5, making it unsuitable for those who want to stream audio content. At this price point, buyers face strong competition. Devices like the Sony CRE-E10 and Lexie B2 Plus offer substantially higher overall scores in the same price range. The BlaidsX Neuro may suit users who primarily need help with face-to-face conversation in quiet spaces and don't require streaming capabilities, but those seeking versatile performance should consider alternatives.

The Resound Vivia 9 60S microRIE is a premium prescription behind-the-ear hearing aid released in 2025, currently available at $3,798. In HearAdvisor's lab testing, it earned a B grade with a SoundScore of 3.9/5, ranking #27 of 36 prescription hearing aids tested. This device demonstrates a mixed performance profile in our testing. Own-voice comfort is a notable strength, scoring 3.4/5—a solid result that sits 0.65 points above the category average, which may appeal to users sensitive to the hollow or boomy sound of their own speech. Speech clarity in quiet environments also performs well at 3.4/5, slightly above the category average. However, the Vivia 9 shows significant limitations in challenging listening situations. Speech in noise scored just 1.1/5, falling 0.81 points below the prescription hearing aid average—a substantial gap that suggests difficulty in restaurants, group conversations, or other noisy environments. Feedback handling, while strong in absolute terms at 4.2/5, still lands 0.51 points below what we typically see from prescription devices. Music streaming quality is mixed at 2.6/5, essentially matching the category average. At this premium price point, the Vivia 9 faces stiff competition. Several same-priced alternatives, including the Phonak Sphere Infinio and Oticon Intent, achieved notably higher overall scores in our testing. Consumers prioritizing noise performance may want to explore these options or consider lower-priced alternatives like the Sennheiser All Day Clear that delivered stronger overall results in our lab.